Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab(TM) for the Treatment of Systemic Sclerosis (Scleroderma)

Industry News

Corbus Pharmaceuticals, a clinical stage drug development company based in Norwood, MA, announced that the U.S. FDA has granted Orphan Drug Designation for its resunab ™ for the treatment of systemic scelerosis.  Systemic sclerosis is a rare autoimmune disease characterized by abnormalities in blood vessels and thickening of the skin caused by pathological accumulation of collagen.  It represents the highest mortality rate of any autoimmune rheumatic disease.  Currently, there is no cure for this disorder and no FDA-approved therapy either.  Resunab is a synthetic oral agonist for CB2 receptor that is expressed on activated immune cells.  It has been shown that CB2 activation leads to resolution of inflammation and termination of fibrosis.  Preclinical and phase I studies have shown favorable safety, tolerability and pharmacokinetic profile for Resunab.


Original article:

Subscribe to WXPress

Receive our newsletter and information on upcoming events.